Agminated benign vascular tumour successfully treated with trametinib

Vascular tumours are caused by the neoplastic transformation of cells constituting vascular structures. Traditionally, treatment options include surgical approaches such as resection, embolization/sclerotherapy, or laser therapy, and medical treatments such as corticosteroids, beta-blockers, and chemotherapy. The investigation of genetic mutations underlying vascular anomalies has recently provided new insights into the genetic aetiology of these lesions,1 giving rise to personalized, targeted medical treatment that may potentially be safer and more effective. Here, we describe a patient who presented with a reactive, locally disseminated vascular tumour that failed conventional treatments. Identifying a somatic mutation in the NRAS gene promoted the treatment with trametinib, which resulted in the rapid regression of the tumour.